Tags |
|
|
Links |
|
|
Top Articles - Reducing Tax on Investments: Minimising Capital Gains Tax
Capital gains tax (CGT) is payable on the sale not only of stocks and shares but also of anything other than household goods and personal effects up to the value of ?6,000 and private motor vehicles. Subject to certain exceptions, you do not pay CGT on any gain you make when you sell your home. Nor, o
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
n the other hand, can you set off any loss against gains made elsewhere.
Capital losses are set off against capital gains in the same tax year and after that there is an annual exemption, currently ?7,500. As a result, few people pay CGT.
If the net result of a year's transactions before the annual
Capital losses are set off against capital gains in the same tax year and after that there is an annual exemption, currently ?7,500. As a result, few people pay CGT.
If the net result of a year's transactions before the annual
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
exemption is a loss, it can be carried forward to succeeding years. The annual exemption cannot be carried forward, but can be applied to the net gains for a year before any loss brought forward which, if not then used, can be carried forward again.
The following investments are exempt from CGT:
gilt edged stock
company debentures and loan stocks
friendly society savings schemes
ISAs and PEPs
company share option schemes
enterprise investment schemes and venture capital trusts
commercial forestry
As with tax on inc
The following investments are exempt from CGT:
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
As with tax on inc
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ome, investments which are free of capital gains tax need to be good investments in their own right. A taxed gain is better than no gain at all.
Indexation and taper relief
For purchases before April 1998 the cost can be indexed, that is adjusted by the cumulative rate of inflation (RPI) betw
Indexation and taper relief
For purchases before April 1998 the cost can be indexed, that is adjusted by the cumulative rate of inflation (RPI) betw
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
en purchase and April 1998. However, indexation cannot be taken beyond breakeven, i.e. it cannot be used to create a loss.
If you held any shares before 6 April 1998, it is a good idea to calculate the indexed cost now, as it will not change. This can be done by using the CW indexation allowances for
If you held any shares before 6 April 1998, it is a good idea to calculate the indexed cost now, as it will not change. This can be done by using the CW indexation allowances for
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
April 1998, available in Inland Revenue leaflet CGT1, which can be obtained from your local tax office.
From April 1998, indexation was replaced by taper relief which is based on the length of ownership. It only applies to shares held for at least three complete years, although an extra year is adde
From April 1998, indexation was replaced by taper relief which is based on the length of ownership. It only applies to shares held for at least three complete years, although an extra year is adde
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
to the total for shares owned on 17 March 1998.
The percentage of the gain chargeable reduces to 95% after the third complete year and by a further 5% for each successive year, to a minimum of 60% after ten complete years.
For example, if you bought shares in August 1996 and sold them in June 2001,
The percentage of the gain chargeable reduces to 95% after the third complete year and by a further 5% for each successive year, to a minimum of 60% after ten complete years.
For example, if you bought shares in August 1996 and sold them in June 2001,
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
the taxable gain would be calculated as follows:
- The original cost would be increased to 5 April 1998 in accordance with the CW indexation allowance for the period, to give the indexed cost.
- The excess of the selling value over the indexed cost gives the taxable gain before taper
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
relief.
Although the shares have only been held for two full years since April 1998, as the shares were held on 17 March 1998 an extra year is added, making a total of three years, so taper relief reduces the chargeable gain to 95%
More favourable taper relief applies to busines
More favourable taper relief applies to busines
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
s assets, and since 6 April 2000 it also applies to all shares owned in your employing company and to all shares in unquoted and AIM quoted companies.
The percentage of the gain chargeable in this case reduces to 87.5% after the first complete year, to 75% after two years and 50% after three, to a mi
The percentage of the gain chargeable in this case reduces to 87.5% after the first complete year, to 75% after two years and 50% after three, to a mi
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
nimum of 25% after four years.
Where shares qualify as business assets only from 6 April 2000, the gain for shares owned on that date has to be apportioned between the two periods.
Calculating the taxable gain
The method of calculating the chargeable capital gain, following the introduction
Where shares qualify as business assets only from 6 April 2000, the gain for shares owned on that date has to be apportioned between the two periods.
Calculating the taxable gain
The method of calculating the chargeable capital gain, following the introduction
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
f taper relief.
The complications of indexation and taper relief can be ignored if your gross gains for a year do not exceed the annual exemption, currently ?7,500.
Reinvestment relief
Chargeable gains on disposals can be deferred indefinitely if the amounts realised are reinvested in new sh
The complications of indexation and taper relief can be ignored if your gross gains for a year do not exceed the annual exemption, currently ?7,500.
Reinvestment relief
Chargeable gains on disposals can be deferred indefinitely if the amounts realised are reinvested in new sh
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
are issues from qualifying companies under the Enterprise Investment Scheme.
Tax payable
The net chargeable gain for the year is added to your income and is taxed at 10% if any falls within the personal allowance or the 10% band, at 20% for any within the basic rate band (not 22% as for incom
Tax payable
The net chargeable gain for the year is added to your income and is taxed at 10% if any falls within the personal allowance or the 10% band, at 20% for any within the basic rate band (not 22% as for incom
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
) and 40% thereafter. CGT liability cannot be set against personal allowances.
Annual planning
This is mainly a matter of ensuring you make use of your annual tax free allowance.
You should keep a running record of your sales during each financial year (starting 6 April), with a note of the
Annual planning
This is mainly a matter of ensuring you make use of your annual tax free allowance.
You should keep a running record of your sales during each financial year (starting 6 April), with a note of the
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
gain or loss, after adjusting for indexation and taper relief.
Check on the cumulative position at the beginning of March. If you have a substantial amount of your annual allowance still available, then take a look at the unrealised gains in your portfolio.
Bed and breakfasting
Before 17 Mar
Check on the cumulative position at the beginning of March. If you have a substantial amount of your annual allowance still available, then take a look at the unrealised gains in your portfolio.
Bed and breakfasting
Before 17 Mar
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
h 1998, any unused annual allowance could be applied to unrealised gains before the end of the tax year by selling the shares one day and buying them back the next. This has been stopped by introducing a minimum 30 day interval between selling and buying back, otherwise the two transactions will be ig
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
nored for CGT purposes.
It is of course possible to take the risk of being out of the market for 30 days.
Other alternatives are:
It is of course possible to take the risk of being out of the market for 30 days.
Other alternatives are:
- If you have not used all your current year's ISA allowance or have uninvested amounts in a PEP, then you can 'bed and ISA' or 'bed and PEP', that is buy back i
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
to an ISA or PEP.
If you are married you can sell and your spouse buy back (or vice versa).
You can buy a similar share (e.g. BP for Shell) or your best choice of new investment.
In all these alternatives the sale and buy back can be done simultaneously, so there is no
In all these alternatives the sale and buy back can be done simultaneously, so there is no
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
risk of adverse price movement overnight.
The disadvantage is that costs of both selling and buying (including stamp duty) are incurred, although some stockbrokers will forgo some or all of their commission on the second transaction. Also you lose the difference between the buying and selling prices
The disadvantage is that costs of both selling and buying (including stamp duty) are incurred, although some stockbrokers will forgo some or all of their commission on the second transaction. Also you lose the difference between the buying and selling prices
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/102122/toparticles-Reducing-Tax-on-Investments-Minimising-Capital-Gains-Tax.html">Reducing Tax on Investments: Minimising Capital Gains Tax</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/102122/toparticles-Reducing-Tax-on-Investments-Minimising-Capital-Gains-Tax.html]Reducing Tax on Investments: Minimising Capital Gains Tax[/url]
Related Articles:
Having Your Sandwich and Eating It; a Business Students Guide to Securing a Placement
How Promotional Products Are Used In Marketing
Secret No 2: How to Make Friends in Runescape
Bookmark it:
|